Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Niagen Bioscience's Enterprise Value is €150.0 Mil.
Niagen Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €4.9 Mil. Therefore, Niagen Bioscience's EV-to-OCF for today is 30.91.
The historical rank and industry rank for Niagen Bioscience's EV-to-OCF or its related term are showing as below:
FRA:OCD1'
s EV-to-OCF Range Over the Past 10 Years
Min: -1506.89 Med: -8.86 Max: 243.97
Current: 29.61
During the past 13 years, the highest EV-to-OCF of Niagen Bioscience was 243.97. The lowest was -1506.89. And the median was -8.86.
FRA:OCD1's EV-to-OCF is ranked worse than 86.86% of 2001
companies
in the Consumer Packaged Goods industry
Industry Median: 8.07
vs FRA:OCD1: 29.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Niagen Bioscience's PE Ratio (TTM) for today is calculated as:
Niagen Bioscience's share price for today is €2.60.
Niagen Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.161.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Niagen Bioscience EV-to-OCF Related Terms
Niagen Bioscience EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OCD1 vs CAMP, ALEC, ELDN: EV-to-OCF Comparison
For the Packaged Foods subindustry, Niagen Bioscience's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience EV-to-OCF vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Niagen Bioscience's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's EV-to-OCF falls into.
Niagen Bioscience's current Enterprise Value is €150.0 Mil.
Niagen Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (FRA:OCD1) has a EV-to-OCF of 30.91 as of Sep. 21, 2026. According to the industry distribution chart, Niagen Bioscience ranks #1738 out of 2001 companies in the Consumer Packaged Goods industry, placing it in the top 86.9%.
Is Niagen Bioscience's EV-to-OCF too high?
Niagen Bioscience's current EV-to-OCF is 30.91. The Consumer Packaged Goods industry median EV-to-OCF is 8.07. Niagen Bioscience's value of 30.91 is 283% above this industry median. Based on the distribution chart, Niagen Bioscience ranks #1738 out of 2001 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Niagen Bioscience has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's EV-to-OCF compare to CAMP and ALEC?
According to the Consumer Packaged Goods industry distribution chart, Niagen Bioscience ranks #1738 out of 2001 companies for EV-to-OCF. This places Niagen Bioscience in the lower half of its industry. The industry median EV-to-OCF is 8.07. Niagen Bioscience's value of 30.91 is 283% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Consumer Packaged Goods company?
The median EV-to-OCF among Consumer Packaged Goods companies is 8.07, based on 2,001 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current EV-to-OCF of 30.91 is 283% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median EV-to-OCF is 8.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current EV-to-OCF is 30.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Niagen Bioscience (FRA:OCD1) has a current EV-to-OCF of 30.91. The stock's GF Value™ is €3.77, compared to a current price of €2.60 — trading 31% below its estimated fair value. The current EV-to-OCF is 30.91 and 283% above the Consumer Packaged Goods industry median of 8.07. Niagen Bioscience's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current EV-to-OCF is 30.91 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.60 is trading 31% below its estimated GF Value™ of €3.77.
Key valuation signals for FRA:OCD1:
EV-to-OCF: 30.91
GF Value™: €3.77 vs. price of €2.60 (31% below fair value)
Industry Position: 283% above the Consumer Packaged Goods median (#1738 of 2001)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score
Get the complete analysis for FRA:OCD1
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
